Group 1: Company Performance - In Q1 2023, the company's revenue reached ¥69,223,571.97, representing a year-on-year growth of 25.39% [3] - The net profit attributable to shareholders was ¥16,679,264.59, with a year-on-year increase of 27.35% [3] - The company aims to continuously improve management levels to ensure stable development and reward investors with good performance [3] Group 2: Research and Development - In 2022, the company invested a total of ¥8,862,117.87 in R&D, accounting for 4.20% of its revenue [5] - Key R&D projects included studies on the consistency evaluation of Metronidazole tablets and the preparation process of Calcium Gluconate [4][5] Group 3: Future Development Directions - The company will focus on optimizing existing formulations and traditional Chinese medicine products, enhancing sales team construction, and expanding sales channels [5] - Plans to increase the sales scale of proprietary brand products and improve profitability are also highlighted [5] Group 4: Strategic Initiatives - The company has established a joint venture in Shanghai to leverage resources and R&D advantages for developing traditional Chinese medicine products [6] - Currently, there are no stock incentive plans, but the company will disclose any future plans in accordance with regulations [7] Group 5: Product Supply - The company supplies Calcium Gluconate and Zinc Gluconate raw materials to partners such as Auno, Haya, and Furen Jingshen [7]
新赣江(873167) - 关于接待机构投资者调研情况的公告